Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri

Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician's insufficient knowledge. The study aimed to evaluate the patterns a...

Full description

Saved in:
Bibliographic Details
Published in:The South African journal of psychiatry Vol. 30; no. 1; p. 2133
Main Authors: Shettima, Falmata B, Wakil, Musa A, Sheikh, Taiwo L, Abdulaziz, Mohammed, Wakawa, Ibrahim A, Beida, Omeiza
Format: Journal Article
Language:English
Published: South Africa African Online Scientific Information Systems (Pty) Ltd t/a AOSIS 2024
AOSIS
Subjects:
Analysis
Antipsychotic drugs
antipsychotics
Complications and side effects
Diseases
Dosage and administration
Drug therapy
hyperprolactinaemia
Hyperprolactinemia
Medical research
Medicine, Experimental
nigeria
Original Research
Patient compliance
Prolactin
Risk factors
Schizophrenia
Schizophrenics
Statistics
Trifluoperazine
Nigeria
antipsychotics
prolactin
hyperprolactinaemia
schizophrenia
Nigeria
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician's insufficient knowledge. The study aimed to evaluate the patterns and correlates of hyperprolactinemia among patients with schizophrenia on antipsychotic medications. The study was conducted in a psychiatric facility in Maiduguri, Northeastern Nigeria. A total of 209 patients with schizophrenia were evaluated through a cross-sectional design and assayed for serum prolactin with ELISA Kits. Frequencies and percentages were tabulated for categorical variables. Variables with significant associations with hyperprolactinaemia on chi-square ( < 0.05) were subjected to logistic regression analysis. The prevalence of hyperprolactinaemia was 45.9% in all patients on antipsychotic medication. The prevalence because of the use of typical and atypical antipsychotics was 51.5% and 25.0%, respectively. Hyperprolactinaemia was significantly associated with typical antipsychotics (β = 0314, = 0.002), high overall drug dosage (β = 2.340, = 0.003), high-dose typical antipsychotics (β = 3.228, = 0.000), twice daily dosing frequency (β = 2.751, = 0.001) and polypharmacy (β = 1.828, = 0.0024). The findings support that patients on typical, high-dose antipsychotic medications and polypharmacy have a high prevalence of hyperprolactinaemia. As hyperprolactinaemia is often undetectable, screening and patient psycho-education on the significance of the signs and symptoms of hyperprolactinaemia is required for necessary clinical intervention. The study provides evidence for the rational use of antipsychotic medications in sub-Saharan Africa.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1608-9685
2078-6786
1608-9685
2078-6786
DOI:10.4102/sajpsychiatry.v30i0.2133